Table 1

Genome-wide significant signals associated with LADA

SNPChromosomePosition (b37)Reference/other alleleEffect allele frequency (case/control subjects)OR95% CIPGene
LADA (n = 2,634) vs. population control subjects (n = 5,947)
 rs9273368632626475A/G0.50/0.283.1152.855–3.3987.87 × 10−143HLA-DQB1
 rs24766011114377568A/G0.159/0.1021.7171.539–1.9157.21 × 10−22PTPN22
 rs689112182224T/A0.802/0.7261.4831.363–1.6131.07 × 10−19INS
 rs731061512111865049C/G0.553/0.4921.2841.193–1.3834.92 × 10−11SH2B3
LADA (n = 2,779) vs. case subjects with type 2 diabetes (n = 10,396)
 rs9273368632626475A/G0.43/0.3012.4392.222–2.6763.17 × 10−78HLA-DQB1
 rs689112182224T/A0.783/0.7151.4731.352–1.6059.86 × 10−19INS
 rs24766011114377568A/G0.173/0.1401.5291.38–1.6934.52 × 10−16PTPN22
 rs318450412111884608C/T0.544/0.521.241.151–1.3361.77 × 10−8SH2B3
LADA (n = 2,454) vs. case subjects with type 1 diabetes (n = 968)
 rs9273368632626475A/G0.415/0.650.3350.256–0.3858.46 × 10−40HLA-DQB1
  • We performed three genome-wide association approaches, first for LADA vs. population control subjects (top), then for LADA vs. type 2 diabetes (middle), and finally for LADA versus type 1 diabetes (bottom). ORs are given for the LADA risk allele, except for rs9273368 in LADA vs. type 1 diabetes, to illustrate that the type 1 diabetes risk allele was depleted in LADA.